Weekly SCD Practice Update

Transdermal curcumin gel (VAS-101 drug candidate) improves the microcirculation and tissue oxygenation in a rat model of sickle cell vaso-occlusive episode

William H Nugent, PhD, Richard Prince, PhD, Joel Friedman, MD, PhD, Bjorn K Song, PhD

Key Findings

  • Purpose

    This preclinical study investigated whether VAS-101, a transdermal curcuminoid gel, could help maintain microvascular perfusion and tissue oxygenation during an experimentally induced vaso-occlusive challenge. The rationale included the proposed ability of curcuminoids to enhance endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) signaling. However, eNOS activity and NO mediation were not directly confirmed in this experiment.

  • Population (Model)

    The study included 16 male Sprague Dawley rats, aged 8–9 weeks and weighing 250–350 g, randomly assigned to Sham and VAS-101 groups (eight animals per group). Investigators induced localized vaso-occlusive physiology through exchange transfusion (ET) with isolated human homozygous sickle hemoglobin (HbSS) red blood cells. The VAS-101 group received 0.1 mL of gel containing 4 mg of curcuminoids, applied to shaved skin 30 minutes before ET. Researchers assessed arteriolar diameter, interstitial oxygen tension in spinotrapezius muscle, mean arterial pressure (MAP), heart rate, and arterial blood gases over a two-hour experimental period.

  • Headline Result

    The strongest and most consistent treatment-associated signal was in tissue oxygenation. Across the three measurement regions, oxygenation declined by an average of 28 ± 5% in the VAS-101 group versus 41 ± 8% in Sham (P < .001). At the distal site, Sham animals experienced a 52 ± 13% decline, and tissue oxygenation crossed the study’s 20 mmHg hypoxia threshold. VAS-101-treated animals did not fall below this threshold in any region during observation. VAS-101 was associated with maintenance of arteriolar caliber, while Sham animals showed more evident constrictive trends. However, post-ET between-group differences in arteriolar diameter were not detected at most assessed time points; a significant difference was reported in the proximal region at ET120, where Sham was lower than both baseline and VAS-101.

    The tissue-oxygenation benefit persisted over the two-hour observation period. The between-group MAP advantage was most apparent immediately after ET and at ET15, then diminished as blood pressure recovered in both groups. All 16 animals survived to ET120. No adverse incidents or VAS-101-related adverse effects were observed during the anesthetized, two-hour experimental period.

  • Why It Matters

    The findings contribute to preclinical investigation of the microvasculature as a potential therapeutic target in SCD. Preserving tissue oxygenation during vaso-occlusive stress could be relevant to the cycle of hypoxia, sickling, and impaired microvascular flow. The more consistent oxygenation results, compared with the region- and time-specific arteriolar findings, are important when interpreting the study’s vascular effects. The transdermal formulation is intended to address challenges associated with oral curcumin delivery, including poor bioavailability. The experiment provides an early signal that this formulation may influence tissue oxygenation in an acute animal model. It does not establish clinical efficacy, prevention of vaso-occlusive episodes (VOEs), or pain relief in people with SCD. The proposed eNOS/NO pathway remains a hypothesis rather than a demonstrated mechanism. Further investigation would be needed to establish whether this pathway explains the observed oxygenation effects or whether other mechanisms contribute.

  • Evidence Gaps & Limitations
    The study involved a small sample of male rats and an acute, experimentally induced model. It cannot reproduce the full complexity of human SCD, including chronic anemia, recurrent VOEs, organ injury, and variation in patient characteristics and treatment histories. The two-hour observation period limits conclusions about durability, repeated dosing, and safety beyond the anesthetized experiment. The pretreatment design also means the study does not establish whether VAS-101 has an effect when administered after a VOE has begun. Arteriolar findings showed limited between-group statistical separation at most time points, despite the significant proximal-region result at ET120. The proposed eNOS/NO mechanism was not directly measured. The study also did not measure blood or tissue curcuminoid concentrations, limiting pharmacokinetic interpretation and the ability to relate exposure to the observed effects.

Source: Journal of Sickle Cell Disease- “Transdermal curcumin gel (VAS-101 drug candidate) improves the microcirculation and tissue oxygenation in a rat model of sickle cell vaso-occlusive episode”

Regulatory & Guideline Watch

VAS-101 is an investigational preclinical drug candidate in the context of this study. The findings do not establish a new clinical recommendation or support changes to existing SCD prevention or acute VOE management protocols. The authors identify further investigation as important, including work to assess the proposed mechanism and the treatment’s effects in additional models and settings. Testing during established VOEs is a potential area for future research, not an outcome demonstrated by this experiment or a formal requirement established by the article.

Stay Informed. Stay Empowered.

Subscribe to our newsletter for the latest updates on sickle cell research, events, and resources.

Get expert insights, patient stories, and ways to get involved, delivered straight to your inbox.

Join our community today!